123 results about "Hepatic carcinoma" patented technology

The invention relates to a hepatocellular carcinoma gene knockout target library based on multiple omics and a screening method of the hepatocellular carcinoma gene knockout target library, and the gene knockout target library for precise treatment of hepatocellular carcinoma is finally obtained through data collection and integration, data screening and target verification in sequence. According to the invention, through multi-omics data integration and bioinformatics analysis, key driving genes of hepatocellular carcinoma are systematically screened, and the important effects of the genes in occurrence, development, metastasis, drug resistance and immune escape of hepatocellular carcinoma are disclosed; the genes not only deepen the understanding of the hepatocellular carcinoma molecular mechanism, but also provide important theoretical basis and potential intervention targets for the development of targeted therapy and personalized therapy strategies.

The invention belongs to the field of microorganisms, and particularly relates to a pleurotus citrinopileatus strain for producing ergothioneine and a preparation method and application of ergothioneine. The pleurotus citrinopileatus strain is preserved in China General Microbiological Culture Collection Center (CGMCC). According to the preparation method of the ergothioneine, lactose and casein peptone are used as a carbon source and a nitrogen source of a liquid fermentation culture medium. The pleurotus citrinopileatus strain is used for high yield of ergothioneine, and the ergothioneine produced by fermentation is used for relieving oxidative stress damage of hepatoma carcinoma cells HepG2.

The invention discloses a 5-substituted-3-(arylaminoethyl) benzoxazolone compound and a preparation method and application thereof.The compound takes CO2 as a carbonyl source, the preparation method is simple, raw materials are easy to obtain, and the compound has a good anti-cancer effect on the activity of cancer cells and particularly has a remarkable anti-cancer effect on the cancer cells such as HCCLM3 (human hepatoma carcinoma cells) and MCF-7 (human breast cancer cells).

The invention relates to the technical field of hepatocellular carcinoma, in particular to a hepatocellular carcinoma prognosis model construction method based on immunogen cell death related genes and application, and an accurate prognosis prediction model is constructed by integrating the immunogen cell death related genes (IRGs) and molecular characteristics of hepatocellular carcinoma. A training set and a verification set provided by TCGA and ICGC databases are utilized, so that the model can perform effective sample analysis under a large-scale data background. Through consistency clustering analysis, the optimal clustering number is determined, the samples are orderly divided into different molecular subtypes, and it is ensured that the samples in each subtype have similar molecular characteristics. According to the invention, the capability of capturing liver cancer heterogeneity on the molecular level of the model is increased, so that the accuracy of prognosis prediction is improved.

The invention discloses a method for detecting the assembly change of an ASGPR (asialoglycoprotein receptor) on the surface of a hepatocyte, which comprises the following steps: carrying out specific labeling on the ASGPR on the surface of the hepatocyte through an antibody, and carrying out fluorescence imaging on the ASGPR on the surface of a cell membrane, the purpose of detecting ASGPR assembly change on the liver cell membrane is achieved by statistically analyzing the number of ASGPR protein positioning points on the surface of the cell membrane and aggregation parameters. According to the method, the distribution and aggregation condition of the ASGPR on the cell surface is measured through the nanoscale resolution, the change of the ASGPR in the cell membrane assembly relation is detected, damage to sample cells is small, the time cost of the experimental process is small, protein positioning is accurate, and as the ASGPR is an endocytosis receptor specifically existing on the surface of hepatocellular carcinoma cells, the detection result is accurate, and the detection accuracy is high. Efficient treatment can be achieved through a drug delivery system formed by targeting ASGPR, ASGPR can be better known by observing the assembly difference of ASGPR on the surface of a cell membrane from the nanoscale, and the method has wide application prospects in the field of medical detection and diagnosis.

The invention belongs to the technical field of cancer resistance, and relates to a preparation method and application of curcumin-loaded composite nanoparticles. Sodium alginate and carboxymethyl chitosan chelated metal calcium ions are synthesized by adopting a liquid phase precipitation method to form double-skeleton packaged curcumin and manganese carbonate doped CuratCMCS / SA-CaCO3 / MnCO3 nanoparticles, the characteristics of poor water solubility and low bioavailability of curcumin are overcome, the drug loading rate is improved, a compact calcium shell structure also has acid responsiveness, and the drug loading capacity is improved. And the drug can be specifically disintegrated and released in an acidic tumor microenvironment. The nanoparticles show remarkable cytotoxicity to human hepatoma carcinoma cells HepG2, have a remarkable inhibition effect and can effectively induce cell apoptosis.

This invention belongs to the field of medicinal chemistry, specifically relating to 2-[2-methyl-6-(quinoline-3-yl)nicotinyl]-N-phenylhydrazine-1-formamide derivatives, their preparation methods, and applications. This invention is the first to synthesize 2-[2-methyl-6-(quinoline-3-yl)nicotinyl]-N-phenylhydrazine-1-formamide derivatives. Furthermore, the preparation method for these derivatives features low raw material costs, high yield, and a simple and easily controllable reaction process, making it suitable for industrial production. Moreover, these derivatives exhibit high NR4A1 protein-level inhibitory activity and can be used to prepare anti-hepatocellular carcinoma drugs.

The invention discloses a liver cancer microvascular infiltration prediction method and system, and relates to the technical field of medical image analysis and artificial intelligence, and the method comprises the steps: obtaining the liver data of a prediction object, carrying out the preprocessing of the liver data of the prediction object, and obtaining the processed liver data of the prediction object, the liver data of the predicted object comprises the pathology of the predicted object, multi-stage enhanced image information and liver related data; screening the processed liver data of the prediction object to obtain a radiomics characteristic index associated with the liver cancer microvascular infiltration degree, and inputting the radiomics characteristic index associated with the liver cancer microvascular infiltration degree into a pre-established liver cancer microvascular infiltration prediction model, outputting to obtain a trained liver cancer microvascular infiltration prediction model; and checking and comparing the trained liver cancer microvascular infiltration prediction model by adopting a mode of calculating an AUC value, determining an optimal liver cancer microvascular infiltration prediction model according to a comparison result, and realizing prediction of liver cancer microvascular infiltration through the optimal liver cancer microvascular infiltration prediction model.

The invention belongs to the technical field of gene engineering, and particularly relates to application of an SSRP1 and / or SUPT16H gene inhibitor in treatment of hepatocellular carcinoma. The invention provides an application of an inhibitor of SSRP1 and / or SUPT16H genes in preparation of a pharmaceutical composition for treating cancers. According to the invention, the high expression of SSRP1 and SUPT16H is obviously related to poor prognosis through pan-cancer analysis of SSRP1 and SUPT16H. In liver cancer, the FACT is preferentially enriched in liver cells, and the expression of the FACT is increased along with the increase of quasi time, which indicates that the FACT participates in tumor evolution and transcriptome reprogramming processes. According to the invention, FK866 and NPK76-II-72-1 are screened as potential inhibitors through drug sensitivity analysis, and FK866 and NPK76-II-72-1 are screened as the potential inhibitors. Therefore, an inhibitor of the SSRP1 and / or SUPT16H gene can be used for prognosis evaluation of the hepatocellular carcinoma patient, and can be used as a treatment target of the hepatocellular carcinoma patient.

The embodiment of the invention discloses a heavy chain variable region and a light chain variable region of an anti-GPC3 monoclonal antibody and application of the heavy chain variable region and the light chain variable region. The high-affinity anti-GPC3 sequence is obtained through screening, the binding specificity of the high-affinity anti-GPC3 sequence and the GPC3 antigen is high, and dissociation is slow. The sequence is used as an extracellular targeting domain to construct GPC3-CAR, after macrophages are transduced through lentivirus, CAR-M can specifically recognize GPC3 positive target cells, activate intracellular signal channels and remarkably improve in-vitro phagocytosis and killing activity, the hepatoma cell lysis effect is better, and technical support is provided for anti-hepatoma application.

The invention discloses application of acid-producing bacteroides in treatment of hepatic fibrosis and hepatocellular carcinoma. In-vitro cell experiments verify that the Bacteroides acidogenes and the culture medium thereof can inhibit LX2 cell fibrosis induced by TGF-beta, can inhibit the activity of LX2, Huh7 and 97H cells and can inhibit the cell proliferation capacity at the same time, and further, in a hepatocellular carcinoma spontaneous animal model induced by diethylnitrosamine and carbon tetrachloride, the application of the Bacteroides acidogenes and the culture medium of the Bacteroides acidogenes and the culture medium of the Bacteroides acidogenes and the culture medium of the Bacteroides acidogenes in the hepatocellular carcinoma spontaneous animal model has the advantages of being capable of inhibiting the fibrosis of the LX2 cells induced by the TGF-beta and inhibiting the proliferation capacity of the cells. The inhibition effect of the acid-producing bacteroides on hepatic fibrosis and liver cancer progression is verified; the acid-producing bacteroides is recognized as probiotics and has low side effect risk, so that the acid-producing bacteroides has a good clinical application prospect.

The application relates to a synthesis method of red luminescent carbon dots with a targeting diagnosis and treatment potential of hepatocellular carcinoma, which comprises the following steps: 1) adding 5-fluorouracil and indocyanine green into deionized water, uniformly mixing, and forming a uniform mixed solution; 2) heating the mixed solution obtained in the step 1) at 160-200 DEG C for 5-9 h, and cooling to room temperature; 3) filtering and dialyzing the solution obtained in the step 2), and obtaining a pure 5-FICD solution; and 4) freeze-drying the solution obtained in the step 3), and obtaining the product. The method takes anticancer drug 5-fluorouracil and photosensitizer indocyanine green as precursors, synthesizes a low-toxicity red light carbon dot through a simple hydrothermal method, improves the shortcoming that a chemotherapy drug has a large side effect, and realizes the targeted killing of hepatocellular carcinoma cells.

This invention belongs to the field of biotechnology and pharmaceutical technology, and discloses an ACLY-targeting PROTAC chimera with anti-MASH activity using a glycol chain as the linking chain. Its general structural formula is Formula 1: R is -(CH2-O-CH2). n -, n is 2-6. The PROTAC compound synthesized in this invention is a novel compound. In a high-fat model established using L02 and HepG2 cells, the synthesized PROTAC compound exhibits activity in reducing TG content. Compared with the warhead, the synthesized PROTAC compound shows low toxicity activity in human hepatocellular carcinoma cells HepG2, normal human hepatocytes L02, and human umbilical vein endothelial cells HUVEC, making it a novel, low-toxicity, and highly effective drug for treating non-alcoholic steatohepatitis (NAH). This invention expands the application areas of PROTAC technology while developing a highly effective treatment for NHA.

The disclosure belongs to the field of genetic testing and biomedicine, relating to a method for constructing a prognostic model of hepatoma and an application thereof, comprising 1) obtaining and identifying fibroblasts with high FAP expression; 2) obtaining and identifying TAMs; 3) analyzing co-localization between fibroblasts with high FAP expression obtained and the TAMs obtained previously; 4) communicating and analyzing the fibroblasts with high FAP expression after the localization in the Step 3) with TAMs to obtain CCC ligand-receptor genes; 5) screening the CCC ligand-receptor genes obtained previously based on machine learning to obtain key CCC ligand-receptor genes; and 6) constructing a prognostic model of hepatoma according to the key CCC ligand-receptor genes obtained in the Step 5). The present disclosure provides a method for constructing a prognostic model of hepatoma that can be applied to auxiliary judgment of the prognosis of hepatoma patients and an application thereof.

This invention discloses a method for preparing fucoidan from *Sargassum hemifolia* and its application in the preparation of anti-hepatocellular carcinoma drugs. Experimental results show that *Sargassum hemifolia* fucoidan Fb has a strong inhibitory effect on HepG2 hepatocellular carcinoma cells, significantly stronger than the inhibitory effects of *Sargassum henryi* polysaccharide Fh and *Sargassum fusiforme* polysaccharide SFPS on HepG2 hepatocellular carcinoma cells. After treatment of HepG2 hepatocellular carcinoma cells with *Sargassum hemifolia* fucoidan DF1 and DF2, apoptosis is ultimately induced through the interaction and cooperation of exogenous (death receptor pathway) and endogenous (mitochondrial pathway). *Sargassum hemifolia* fucoidan possesses strong antitumor activity and therefore can be used to prepare anti-hepatocellular carcinoma drugs.

The present invention relates to peptides, antigen-binding proteins, nucleic acids and cells for use in immunotherapy methods.Specifically, the present invention relates to the immunotherapy of cancer, in particular the immunotherapy of fibrolamellar hepatocellular carcinoma.Furthermore, the present invention relates to tumor-associated T cell peptide epitopes and recombinant T cell receptors that can be used, for example, as active pharmaceutical ingredients in vaccine compositions to stimulate anti-tumor immune responses or can be stimulated ex vivo T cells and transferred to patients.

The invention provides an application of a compound WAY-226570 in preparation of an anti-liver cancer drug. The invention firstly finds that WAY-226570 (the molecular formula is C14H10F3N3) can inhibit the proliferation effect and migration and invasion activity of liver cancer cells, and further, the lenvatinib and WAY-226570 are combined to generate a synergistic inhibition effect on the proliferation of the liver cancer cells, so that the lenvatinib can be used as a combined medicine composition to be applied to the preparation of the medicine for preventing and / or treating the liver cancer, and has a clinical application prospect.

The invention discloses application of physcion in preparation of a medicine for reducing liver cell lipid deposition, and particularly relates to application of physcion in preparation of a medicine for preventing and treating lipid deposition fatty liver. In-vitro cell experiments prove that the physcion shows low toxicity and a wide safety range in a human normal hepatocyte line THLE3, a human hepatoma cell line HepG2 and a mouse normal hepatocyte line AML12, and can obviously reduce the level of oleic acid-induced intracellular triglyceride in a dose-dependent manner, so that the physcion can be used for preparing a medicine for treating liver cancer. Oil red O staining results also visually show that lipid droplet accumulation in cells can be effectively reduced; according to the invention, the technical prejudice that the emodin monomethyl ether is regarded as a potential hepatotoxic component in the prior art is overcome, a safe and effective new choice is provided for the treatment of the lipid deposition fatty liver, and the pharmaceutical composition has a wide clinical application prospect.

This invention discloses a nanoparticle-based drug delivery system, MPL@ICC, its synthesis method, and its applications. The MPL@ICC system consists of hollow, porous nano-MnO2, a hydrophilic targeting complex on its surface, and an acid-responsive drug, INH-CA, and a photosensitizer loaded internally. It possesses both targeted transport and controlled release capabilities against human hepatocellular carcinoma cells (HepG2), allowing it to accumulate within these cells and achieve photodynamic therapy (PDT) and free radical-induced immune killing within the tumor. Simultaneously, it directly kills tumor cells and transforms them from non-immunogenic to immunogenic, mediating an anti-tumor immune response and achieving immunogenic cell death (ICD). This overcomes the shortcomings of ICD-induced cancer treatment strategies, which often fail to produce strong and durable therapeutic effects, and does not induce normal cell apoptosis, thus possessing controllability, effectiveness, and safety.

The present invention provides a polypeptide targeting HDAC5 and its application in the preparation of a drug for treating cancer. The polypeptide specifically binds to HDAC5, and the polypeptide is selected from any one or more of SEQ ID NOs: 1-5 and SEQ ID NOs: 11-15. By using HDAC5 as the target protein of the anti-cancer drug and combining AI-assisted design and screening methods, a number of novel polypeptide compounds with anti-cancer activity have been found. These polypeptides have the advantages of specific targeting, low toxicity and low side effects as drugs, and thus have potential application value for development as anti-cancer drugs. In particular, when the polypeptide shown in SEQ ID NO: 1 or 11 is used in cell experiments in the form of SEQ ID NO: 6 or 16 with a cell-penetrating peptide, it is found that its anti-hepatocellular carcinoma activity is the highest.

The invention relates to application of kaempferol in preparation of drugs, food or health care products for preventing or treating liver cancer related to non-alcoholic fatty liver or non-alcoholic fatty liver. According to the kaempferol disclosed by the invention, the liver weight, the liver weight ratio, the tumor quantity and the maximum diameter of the tumor of a mouse with the non-alcoholic fatty liver-related liver cancer are obviously reduced; in histology, the kaempferol can obviously improve hepatic tissue fatty degeneration and liver lipid droplet density, and improve liver cell inflammation and fibrosis degree; kaempferol can obviously reduce the content of cholesterol serum and cholesterol in the liver of a mouse with non-alcoholic fatty liver-related liver cancer, and can reduce liver injury indexes ALT and AST; the kaempferol can obviously reduce the expression level of mRNA related to liver fibrosis of mice with liver cancer related to non-alcoholic fatty liver.

The invention discloses a 3-aryl-4-sulfonyl-1, 3, 4, 5-tetrahydrobenzo [cd]-indole compound in the technical field of organic chemical synthesis, and the structural formula of the 3-aryl-4-sulfonyl-1, 3, 4, 5-tetrahydrobenzo [cd]-indole compound is as follows: # imgabs0 # is prepared by the following steps: sequentially adding beta-4 '-methylindole aryl ethylene, alkyl or aryl sulfonyl chloride and a solvent into a Schlenk tube with a stirrer; the 3-aryl-4-sulfonyl-1, 3, 4, 5-tetrahydrobenzo [cd]-indole compound is prepared by a one-pot method under the condition of constant-temperature organic photocatalysis. The method has the advantages of mild conditions and no need of additional oxidant, and provides a green and efficient preparation method for the sulfonyl-modified 1, 3, 4, 5-tetrahydrobenzo [cd]-indole compound. Meanwhile, according to verification, the 3-aryl-4-sulfonyl-1, 3, 4, 5-tetrahydrobenzo [cd]-indole compound has certain anti-hepatoma activity and can be applied to preparation of anti-hepatoma drugs.

The application belongs to the technical field of molecular biology and drug screening, and provides a method for screening phenylhydrazine sulfate based on a key binding amino acid site of SOCS5-CP and application thereof, which comprises the following steps: key amino acid sites of SOCS5-CP binding are screened through alanine virtual point mutation, and a binding pocket is determined; a ligand molecule is used to perform virtual screening by taking the binding pocket as a docking area, and a compound with the best binding energy is obtained; the obtained drug is screened through AMDET; the selected compound is used for subsequent in-vitro cell experiments, and further screening is performed; the application uses the method of molecular docking and virtual screening in combination with in-vitro experiments for screening, and finds that phenylhydrazine sulfate can be stably combined at the key amino acid sites of SOCS5-CP, in-vitro experiments show that phenylhydrazine sulfate can effectively inhibit the binding of SOCS5-CP, and further down-regulate the protein expression level of HIF1a in hepatoma cells, and also has a significant inhibitory effect on the invasion and migration ability of primary hepatocellular carcinoma.

This invention provides hepatocellular carcinoma-derived growth factor (HDGF) as a target for resistance to tyrosine kinase inhibitors and its related applications. This invention provides the application of HDGF as a target in screening and / or preparing drugs that can improve resistance to tyrosine kinase inhibitors in patients. This invention discovers that high expression of HDGF is one of the mechanisms of resistance to molecularly targeted drugs such as gefitinib and other tyrosine kinase inhibitors. Targeting HDGF can effectively improve resistance to gefitinib in NSCLC and enhance therapeutic efficacy.

The invention discloses triptolide hydrogel, a preparation method thereof and application of the triptolide hydrogel in preparation of a medicine for treating hepatocellular carcinoma, and belongs to the field of biological medicine. The stable injectable hydrogel drug is prepared by utilizing the self-assembly capability of glycyrrhizic acid saponins and loading triptolide, and while the anti-tumor effect of triptolide is played, the toxic and side effects are reduced by virtue of the targeting and anti-inflammatory effects of glycyrrhizic acid, and accurate treatment of liver cancer is realized.

Herein, based on Boolean operators, DNA logic gate complexes are constructed to obtain True (fluorescence signal recovery) or False (fluorescence signal quenching) value using a molecular beacon acting as output. A DNA logic gate complex is composed of a DNA board and at least two modular logic units of YES and / or NOT gate. First, the DNA board is designed to accommodate individual YES and / or NOT modular logic units. An OR logic gate is composed of the DNA board and at least two YES modular logic units, and when there are multiple YES modular logic units, they are arranged in a parallel manner. A NAND logic gate is composed of a DNA board and at least two NOT modular logic units, and when there are multiple NOT modular logic units, they are arranged in a parallel manner. An IMPLY logic gate comprises at least one YES modular logic unit and at least one NOT modular logic unit as well as the DNA board. The designed DNA logic gate complexes were tested with biomarker miRNAs of hepatocellular carcinoma and successfully computed True / False fluorescence outcomes, exhibiting great potential for applications in the field of diseases diagnosis.

The application belongs to the technical field of medical detection, and discloses a biomarker for diagnosing hepatocellular carcinoma and application thereof. The biomarker comprises a combination of coding nucleic acids of alpha-1-microglobulin, vitronectin, apolipoprotein A1, fibrinogen gamma chain, fibrinogen alpha chain and albumin; and the coding nucleic acids comprise mRNA or cDNA. The application purifies CD147 positive extracellular vesicles from plasma, and performs PCR detection on mRNA of hepatocellular carcinoma biomarkers carried in the extracellular vesicles. A HCC Score diagnosis model is constructed based on detection results of the biomarkers, and has high diagnostic sensitivity and specificity for hepatocellular carcinoma, has great potential in screening of early hepatocellular carcinoma, and has important practical significance for early diagnosis of hepatocellular carcinoma.

The invention discloses application of a 1, 2, 4-oxadiazole compound with a structural characteristic shown in a formula (I) in treatment of hepatocellular carcinoma, and belongs to the technical field of biological medicine. The 1, 2, 4-oxadiazole compound provided by the invention has outstanding hClpP enzyme agonist activity, and has a preferable proliferation inhibition effect on hepatocellular carcinoma cells in vitro, so that the compound shown in the formula (I) has the application of treating hepatocellular carcinoma diseases.

The invention provides a lipid nanoparticle. The lipid nanoparticle comprises a distearoyl phosphatidyl ethanolamine-polyethylene glycol derivative and a saturated fatty acid dimer as shown in a formula (I), wherein the mass ratio of the distearoyl phosphatidyl ethanolamine-polyethylene glycol derivative to the saturated fatty acid dimer is (10-30): (1-10). The saturated fatty acid dimer as shown in the formula (I) is delivered by adopting the distearoyl phosphatidyl ethanolamine-polyethylene glycol derivative, so that intracellular lipid accumulation and lipotoxicity effect can be induced, pyroptosis of tumor cells is promoted, systematic anti-tumor immune response is stimulated, and tumor growth is inhibited. More importantly, the lipid nanoparticles can enhance the sensitivity of liver cancer to PD-1 blocking treatment and significantly improve the combined treatment effect, no obvious toxic or side effect is observed, and the lipid nanoparticles show good clinical application prospects. (I).